BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» Skyhawk’s RNA splicing modifier for Huntington’s disease cleared for Australian trial
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Skyhawk’s RNA splicing modifier for Huntington’s disease cleared for Australian trial
Oct. 24, 2023
No Comments
Skyhawk Therapeutics Inc. has obtained Australian human research ethic committee (HREC) approval to conduct a phase I trial of SKY-0515 for Huntington’s disease.
BioWorld Science
Regulatory
Neurology/psychiatric
Australia
